VIVE Vivesto AB (publ)

0.7136USD7.250 SEK · STO+1.54%Mkt Cap: 7.90M USDP/E: —

Vivesto AB (publ) develops, develops, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product, Paccal Vet, is a formulation of paclitaxel with its XR-17 encapsulation technology…

Key Statistics

Company
Market Cap7.90M USD
Enterprise Value6.20M USD
Revenue (TTM)787 USD
Gross Profit787 USD
Net Income (TTM)-3.35M USD
Revenue/Share0.0001 USD
Last Price0.7136 USD
Fiscal Year EndDec 2025
MR QuarterSep 2026
Employees4
CountrySE
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINSE0028925701
Valuation
P/E (Trailing)—
P/E (Forward)-72.50
PEG—
EV/EBITDA-2.12
EV/Revenue7869.27
P/S10033.43
P/B0.52
EPS (TTM)-0.41 USD
EPS (Forward)-0.0098 USD
52W Range
0.63984% of range2.339
52W High2.339 USD
52W Low0.6398 USD
Profitability
Gross Margin100.00%
Oper. Margin-381912.50%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-27.36%
ROA-22.87%
ROIC-25.38%
ROCE-27.60%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-3.34M USD
CapEx (TTM)969.63K USD
FCF Margin-287146.88%
FCF Yield-28.62%
Net Debt-1.65M USD
Net Debt/EBITDA0.57
Net Debt/FCF—
Balance Sheet
Debt/Equity0.10
Current Ratio1.95
Quick Ratio1.84
Book Value/Sh1.36 USD
Cash/Share0.15 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:100
Split DateMay 20, 2026
Analyst Consensus
Rating0.0 (Hold)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)1.821 USD
Upside (mean)+155.2%
Target Range1.821 USD – 1.821 USD
# Analysts1
Ownership
Shares Out.11.07M
Float6.30M
Insiders47.33%
Institutions9.98%
Technical
SMA 500.7736 (-7.8%)
SMA 2000.8378 (-14.8%)
Beta—
S&P 52W Chg12.00%
Avg Vol (30d)7.98K
Avg Vol (10d)8.89K
Technical Indicators
RSI (14)46.0
MACD-0.1534
MACD Signal-0.1819
MACD Hist.+0.0285
BB Upper0.7636 USD
BB Middle0.7222 USD
BB Lower0.6808 USD
BB Width11.46%
ATR (14)0.0415 USD
Vol Ratio (20d)0.33x

About Vivesto (STO: VIVE)

›

Vivesto (STO: VIVE) is listed on Nasdaq Stockholm, where its shares trade in SEK. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 4 employees.

The shares were at 7.250 SEK on 19 November 2026, down 65.1% over 52 weeks. Its 52-week range is 6.500 SEK to 23.76 SEK: the price is 69.5% below the high and 11.5% above the low.

Its market capitalisation is 80.27M SEK.

Vivesto reports return on equity of -27.4%.

It holds more cash than debt, a net cash position of 16.76M SEK. Its Piotroski F-score is 3 out of 9, a weak reading of its financial health. One analyst covers the stock; their mean price target of 18.50 SEK is 155.2% above the current price. The next earnings report is expected on 11 February 2027.